Anti-bacterial Potential of Nano Calcium Hydroxide as an Intracanal Medication
Evaluation of the Antibacterial Potential of Nano Calcium Hydroxide as an Intracanal Medication: A Randomized Clinical Trial
1 other identifier
interventional
54
1 country
1
Brief Summary
The aim of the study is to evaluate the anti-bacterial potential of Nano Calcium Hydroxide as an intracanal medication in primary endodontic treatment of permanent molars.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Aug 2024
Shorter than P25 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 10, 2023
CompletedFirst Posted
Study publicly available on registry
January 9, 2024
CompletedStudy Start
First participant enrolled
August 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedAugust 19, 2024
August 1, 2024
1.1 years
December 10, 2023
August 16, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
bacterial count
variation in bacterial count between 'nano calcium in hydrogel form' group compared with the other groups. The evaluation will be done by quantitative microbiological assessment test. Three microbiological samples will be collected from each patient. Sterile paper points will be used for collecting intracanal content and it will be sealed in Eppendorf tube until the samples reach laboratory center. Tubes will be labelled as following: S1 - S2 - S3 according to the stage of obtaining the sample. S1: will be obtained after access cavity and patency of canals S2: will be obtained by paper point that match the size of master apical file, after complete cleaning and shaping. S3: will be obtained on the seventh day from the intracanal placement appointment. paper points will be used after complete removal of the intracanal medication from the root canals.
on the seventh day from intercanal medication placement appointment
Secondary Outcomes (3)
periapical healing
participants will be recalled after 6 months from the obturation for radiographic examination
incidence and intensity of pain
Pain intensity will be assessed each day for three days following initial treatment
incidence of flare up
incidence of flare up will be recorded each day after the intracanal medication placment visit until the next visit (after seven days)
Study Arms (3)
Nano calcium hydroxide in hydrogel form
EXPERIMENTALnano calcium hydroxide in hydrogel form is placed in the dry root canals after complete cleaning and shaping procedure.The intracanal medication will be distributed to fill the canals up to the orifice level.
Nano calcium hydroxide in paste form
ACTIVE COMPARATORnano calcium hydroxide in paste form is placed in the dry root canals after complete cleaning and shaping procedure. The intracanal medication will be distributed to fill the canals up to the orifice level.
Conventional calcium hydroxide in paste form
ACTIVE COMPARATORconventional calcium hydroxide in paste form is placed in the dry root canals after complete cleaning and shaping procedure.The intracanal medication will be distributed to fill the canals up to the orifice level.
Interventions
placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Eligibility Criteria
You may qualify if:
- healthy males and females.
- age range between 21-49.
- patients with no physical disability or psychological problems.
- patients presenting with single permanent molar with signs and/or symptoms of apical periodontitis, and having Periapican index ≥ 2.
You may not qualify if:
- pregnant women.
- patients with immune-compromised disease.
- patients with complicated systemic diseases.
- patients who took antibiotics within a period of 1 month.
- patients with known sensitivity to the medicaments or pharmaceuticals used in this study.
- Non-restorable teeth including root fractures, and/or advanced periodontal involvement.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
british university in Egypt - dentistry collage
Cairo, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Shehab Eldin M Saber, doctoral
British University In Egypt
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- official investigator
Study Record Dates
First Submitted
December 10, 2023
First Posted
January 9, 2024
Study Start
August 1, 2024
Primary Completion
September 1, 2025
Study Completion
December 1, 2025
Last Updated
August 19, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share